428 related articles for article (PubMed ID: 28801752)
1. Biosimilar G-CSF versus filgrastim and lenograstim in healthy unrelated volunteer hematopoietic stem cell donors.
Farhan R; Urbanowska E; Zborowska H; Król M; Król M; Torosian T; Piotrowska I; Bogusz K; Skwierawska K; Wiktor-Jędrzejczak W; Snarski E
Ann Hematol; 2017 Oct; 96(10):1735-1739. PubMed ID: 28801752
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the efficacy and safety of original filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) in CD34(+) peripheral hematopoietic stem cell mobilization procedures for allogeneic hematopoietic stem cell transplant donors.
Sivgin S; Karakus E; Keklik M; Zararsiz G; Solmaz M; Kaynar L; Eser B; Cetin M; Unal A
Transfus Apher Sci; 2016 Jun; 54(3):410-5. PubMed ID: 27052362
[TBL] [Abstract][Full Text] [Related]
3. Biosimilar Filgrastim (Tevagrastim, XMO2) for Allogeneic Hematopoietic Stem Cell Mobilization and Transplantation in Patients with Acute Myelogenous Leukemia/Myelodysplastic Syndromes.
Danylesko I; Sareli R; Bloom-Varda N; Yerushalmi R; Shem-Tov N; Shimoni A; Nagler A
Biol Blood Marrow Transplant; 2016 Feb; 22(2):277-283. PubMed ID: 26343949
[TBL] [Abstract][Full Text] [Related]
4. Healthy donor hematopoietic stem cell mobilization with biosimilar granulocyte-colony-stimulating factor: safety, efficacy, and graft performance.
Becker P; Schwebig A; Brauninger S; Bialleck H; Luxembourg B; Schulz M; Tsamadou C; Wiesneth M; Reinhardt P; Mytilineos J; Seidl C; Gattu S; Kaliakina N; Singh P; Schrezenmeier H; Seifried E; Bonig H
Transfusion; 2016 Dec; 56(12):3055-3064. PubMed ID: 27633122
[TBL] [Abstract][Full Text] [Related]
5. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation.
Ataergin S; Arpaci F; Turan M; Solchaga L; Cetin T; Ozturk M; Ozet A; Komurcu S; Ozturk B
Am J Hematol; 2008 Aug; 83(8):644-8. PubMed ID: 18508321
[TBL] [Abstract][Full Text] [Related]
6. Comparison of biosimilar filgrastim, originator filgrastim, and lenograstim for autologous stem cell mobilization in patients with multiple myeloma.
Lisenko K; Baertsch MA; Meiser R; Pavel P; Bruckner T; Kriegsmann M; Schmitt A; Witzens-Harig M; Ho AD; Hillengass J; Wuchter P
Transfusion; 2017 Oct; 57(10):2359-2365. PubMed ID: 28653421
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of biosimilar granulocyte colony-stimulating factor versus originator granulocyte colony-stimulating factor in peripheral blood stem cell mobilization in de novo multiple myeloma patients.
Martino M; Recchia AG; Moscato T; Fedele R; Neri S; Gentile M; Alati C; Vincelli ID; Piro E; Penna G; Musolino C; Ronco F; Molica S; Morabito F
Cytotherapy; 2015 Oct; 17(10):1485-93. PubMed ID: 26188967
[TBL] [Abstract][Full Text] [Related]
8. Biosimilar granulocyte-colony-stimulating factor for mobilization of autologous peripheral blood stem cells in pediatric hematology-oncology patients.
Cesaro S; Tridello G; Prete A; Dallorso S; Cannata E; Massaccesi E; Risso M; De Bortoli M; Caselli D
Transfusion; 2015 Feb; 55(2):246-52. PubMed ID: 25070657
[TBL] [Abstract][Full Text] [Related]
9. The comparison of Filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) as a first line peripheral blood stem cell mobilization strategy in autologous hematopoieitic stem cell transplantation: a single center experience from Turkey.
Sivgin S; Karakus E; Kaynar L; Kurnaz F; Pala C; Keklik M; Zararsiz G; Solmaz M; Eser B; Cetin M; Unal A
Transfus Apher Sci; 2013 Jun; 48(3):315-20. PubMed ID: 23611684
[TBL] [Abstract][Full Text] [Related]
10. High-versus standard-dose filgrastim (rhG-CSF) for mobilization of peripheral-blood progenitor cells from allogeneic donors and CD34(+) immunoselection.
Engelhardt M; Bertz H; Afting M; Waller CF; Finke J
J Clin Oncol; 1999 Jul; 17(7):2160-72. PubMed ID: 10561272
[TBL] [Abstract][Full Text] [Related]
11. Biosimilar filgrastim (leucostim®) have similar efficacy in steady-state hematopoietic progenitor cell mobilization compared to original filgrastim (neupogen®) and lenograstim (granocyte®): A retrospective multicenter study.
Kayıkçı Ö; Tekgündüz E; Kaya AH; Göker H; Aslan A; İskender D; Namdaroglu S; Tetik A; Koçubaba Ş; Altuntaş F
Transfus Apher Sci; 2017 Dec; 56(6):832-835. PubMed ID: 29162397
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of a biosimilar granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in Japanese healthy donors: a prospective study.
Sato K; Ishiyama K; Aoki G; Maruyama H; Tsuji N; Tanabe M; Zaimoku Y; Sato H; Yamazaki H; Yamaguchi M; Takami A; Nakao S
Int J Hematol; 2019 Dec; 110(6):648-653. PubMed ID: 31542851
[TBL] [Abstract][Full Text] [Related]
13. Harvesting peripheral blood progenitor cells from healthy donors: retrospective comparison of filgrastim and lenograstim.
Martino M; Console G; Irrera G; Callea I; Condemi A; Dattola A; Messina G; Pontari A; Pucci G; Furlò G; Bresolin G; Iacopino P; Morabito F
J Clin Apher; 2005 Oct; 20(3):129-36. PubMed ID: 15892086
[TBL] [Abstract][Full Text] [Related]
14. Peripheral blood stem cell mobilization and engraftment after autologous stem cell transplantation with biosimilar rhG-CSF.
Reményi P; Gopcsa L; Marton I; Réti M; Mikala G; Pető M; Barta A; Bátai A; Farkas Z; Borbényi Z; Csukly Z; Bodó I; Fábián J; Király A; Lengyel L; Piukovics K; Torbágyi E; Masszi T
Adv Ther; 2014 Apr; 31(4):451-60. PubMed ID: 24687301
[TBL] [Abstract][Full Text] [Related]
15. The safety and efficacy of hematopoietic stem cell mobilization using biosimilar filgrastim in related donors.
Tsumanuma R; Omoto E; Kumagai H; Katayama Y; Iwato K; Aoki G; Sato Y; Tsutsumi Y; Tsukada N; Iino M; Atsuta Y; Kodera Y; Okamoto S; Yabe H
Int J Hematol; 2022 Jun; 115(6):882-889. PubMed ID: 35397766
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of healthy volunteer stem cell mobilization with filgrastim G-CSF and mobilized stem cell apheresis: results of a prospective longitudinal 5-year follow-up study.
Mueller MM; Bialleck H; Bomke B; Brauninger S; Varga C; Seidl C; Seifried E; Tonn T; Bonig H
Vox Sang; 2013 Jan; 104(1):46-54. PubMed ID: 22827736
[TBL] [Abstract][Full Text] [Related]
17. Lenograstim compared to filgrastim for the mobilization of hematopoietic stem cells in healthy donors.
Pérez-López O; Martín-Sánchez J; Parody-Porras R; Espigado-Tocino I; Noguerol P; Carmona-González M; Pérez-Simón JA
Transfusion; 2013 Dec; 53(12):3240-2. PubMed ID: 23489237
[TBL] [Abstract][Full Text] [Related]
18. Superior mobilisation of haematopoietic progenitor cells with glycosylated G-CSF in male but not female unrelated stem cell donors.
Fischer JC; Frick M; Wassmuth R; Platz A; Punzel M; Wernet P
Br J Haematol; 2005 Sep; 130(5):740-6. PubMed ID: 16115131
[TBL] [Abstract][Full Text] [Related]
19. Use of biosimilar filgrastim compared with lenograstim in autologous haematopoietic stem-cell transplant and in sibling allogeneic transplant.
Uddin S; Russell P; Farrell M; Davy B; Taylor J; Agrawal SG
Ther Adv Hematol; 2015 Apr; 6(2):53-60. PubMed ID: 25830013
[TBL] [Abstract][Full Text] [Related]
20. Biosimilar Filgrastim in Autologous Peripheral Blood Hematopoietic Stem Cell Mobilization and Post-Transplant Hematologic Recovery.
Marchesi F; Mengarelli A
Curr Med Chem; 2016; 23(21):2217-29. PubMed ID: 27183986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
